within Pharmacolibrary.Drugs.ATC.C;

model C07AA19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.02,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07AA19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bupranolol is a non-selective beta-adrenergic antagonist (beta-blocker). It was previously used in the management of hypertension, angina pectoris, and certain cardiac arrhythmias. Due to its very short half-life, it has largely fallen out of clinical use and has been superseded by longer-acting agents. Bupranolol is not widely approved or in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult male volunteers after oral administration.</p><h4>References</h4><ol><li><p>Prakash, A, &amp; Markham, A (1999). Long-acting isosorbide mononitrate. <i>Drugs</i> 57(1) 93–100. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199957010-00008&quot;>10.2165/00003495-199957010-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9951954/&quot;>https://pubmed.ncbi.nlm.nih.gov/9951954</a></p></li><li><p>Mishra, B, Sankar, C, &amp; Mishra, M (2011). Polymer based solutions of bupranolol hydrochloride for intranasal systemic delivery. <i>Journal of drug targeting</i> 19(3) 204–211. DOI:<a href=&quot;https://doi.org/10.3109/1061186X.2010.492520&quot;>10.3109/1061186X.2010.492520</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20550434/&quot;>https://pubmed.ncbi.nlm.nih.gov/20550434</a></p></li><li><p>Cleophas, TJ, Niemeyer, MG, Zwinderman, AH, &amp; van der Wall, EE (2000). Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group. <i>Angiology</i> 51(8) 631–638. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10959515/&quot;>https://pubmed.ncbi.nlm.nih.gov/10959515</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07AA19;
